Your browser doesn't support javascript.
loading
Impact of Hospitalizations on Problematic Medication Use Among Community-Dwelling Persons With Dementia.
Deardorff, W James; Jing, Bocheng; Growdon, Matthew E; Blank, Leah J; Bongiovanni, Tasce; Yaffe, Kristine; Boscardin, W John; Boockvar, Kenneth S; Steinman, Michael A.
Afiliação
  • Deardorff WJ; Division of Geriatrics, University of California, San Francisco, San Francisco, California, USA.
  • Jing B; San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
  • Growdon ME; Division of Geriatrics, University of California, San Francisco, San Francisco, California, USA.
  • Blank LJ; San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
  • Bongiovanni T; Division of Geriatrics, University of California, San Francisco, San Francisco, California, USA.
  • Yaffe K; San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
  • Boscardin WJ; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Boockvar KS; Department of Surgery, University of California, San Francisco, San Francisco, California, USA.
  • Steinman MA; San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
J Gerontol A Biol Sci Med Sci ; 79(11)2024 Nov 01.
Article em En | MEDLINE | ID: mdl-39155601
ABSTRACT

BACKGROUND:

Hospitalizations are frequently disruptive for persons with dementia (PWD) in part due to the use of potentially problematic medications for complications such as delirium, pain, and insomnia. We sought to determine the impact of hospitalizations on problematic medication prescribing in the months following hospitalization.

METHODS:

We included community-dwelling PWD in the Health and Retirement Study aged ≥66 with a hospitalization from 2008 to 2018. We characterized problematic medications as medications that negatively affect cognition (strongly anticholinergics/sedative-hypnotics), medications from the 2019 Beers criteria, and medications from STOPP-V2. To capture durable changes, we compared problematic medications 4 weeks prehospitalization (baseline) to 4 months posthospitalization period. We used a generalized linear mixed model with Poisson distribution adjusting for age, sex, comorbidity count, prehospital chronic medications, and timepoint.

RESULTS:

Among 1 475 PWD, 504 had a qualifying hospitalization (median age 84 (IQR = 79-90), 66% female, 17% Black). There was a small increase in problematic medications from the baseline to posthospitalization timepoint that did not reach statistical significance (adjusted mean 1.28 vs 1.40, difference 0.12 (95% CI -0.03, 0.26), p = .12). Results were consistent across medication domains and certain subgroups. In one prespecified subgroup, individuals on <5 prehospital chronic medications showed a greater increase in posthospital problematic medications compared with those on ≥5 medications (p = .04 for interaction, mean increase from baseline to posthospitalization of 0.25 for those with <5 medications (95% CI 0.05, 0.44) vs. 0.06 (95% CI -0.12, 0.25) for those with ≥5 medications).

CONCLUSIONS:

Hospitalizations had a small, nonstatistically significant effect on longer-term problematic medication use among PWD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Demência / Vida Independente / Hospitalização Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Demência / Vida Independente / Hospitalização Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article